Nairobi — Gay rights groups have hailed the results of the first study to show that an antiretroviral (ARV) drug can prevent HIV as an important step in the fight against HIV, but say that in countries that criminalize homosexuality, the breakthrough is unlikely to have a significant impact.
The Iniciativa Profilaxis Preexposicion or Prexposure Prophylaxis Initiative (iPrEx) study found that daily oral pre-exposure prophylaxis (PrEP) - the use of ARVs to prevent HIV in high-risk groups - reduced HIV infection risk among participants who took the ARV Truvada by an average 43.8 percent. The clinical trial of 2,499 men who have sex with men (MSM) and transgender people was conducted at 11 sites in Brazil, Ecuador, Peru, South Africa, Thailand and the United States.
...